Premier Fund Managers Ltd Reduces Stake in Stevanato Group S.p.A. $STVN

Premier Fund Managers Ltd lowered its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 59.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 21,497 shares of the company’s stock after selling 31,985 shares during the period. Premier Fund Managers Ltd’s holdings in Stevanato Group were worth $441,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in STVN. Farther Finance Advisors LLC purchased a new position in shares of Stevanato Group in the 3rd quarter valued at approximately $44,000. First Horizon Corp purchased a new position in shares of Stevanato Group in the 3rd quarter valued at approximately $50,000. State of Wyoming lifted its stake in shares of Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares during the period. Quantbot Technologies LP purchased a new position in shares of Stevanato Group in the 3rd quarter valued at approximately $68,000. Finally, Van Berkom & Associates Inc. lifted its stake in shares of Stevanato Group by 50.6% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock valued at $93,000 after purchasing an additional 1,215 shares during the period.

Stevanato Group Stock Up 0.2%

STVN stock opened at €18.06 on Friday. Stevanato Group S.p.A. has a twelve month low of €12.89 and a twelve month high of €28.00. The company has a quick ratio of 1.26, a current ratio of 1.76 and a debt-to-equity ratio of 0.23. The firm has a market cap of $5.47 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 1.70 and a beta of 0.75. The business has a 50 day moving average of €15.16 and a 200 day moving average of €18.75.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). Stevanato Group had a net margin of 11.83% and a return on equity of 10.44%. The company had revenue of €273.57 million for the quarter. During the same period in the previous year, the business posted $0.10 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. On average, research analysts forecast that Stevanato Group S.p.A. will post 0.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

STVN has been the subject of a number of research analyst reports. Jefferies Financial Group set a $17.50 target price on Stevanato Group in a research note on Tuesday, February 10th. Morgan Stanley lowered their target price on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, March 6th. KeyCorp lowered their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Citigroup lowered their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Finally, Weiss Ratings cut Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 11th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Stevanato Group Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.